📊

Executive Summary

Preclinical once-weekly TransCon PTH prodrug designed to match YORVIPATH daily exposure over an entire week for improved convenience in hypoparathyroidism

QW_TransCon_PTH

· TransCon prodrug

Preclinical

Target:

Mechanism of Action

Target Biology

No target biology data available.

Clinical Data

No clinical trial data available.

Market Opportunity

Catalysts & Upcoming Events

No catalyst data available.

Data sourced exclusively from public filings, corporate presentations, and published clinical data. For informational purposes only. Not investment advice. Satya Bio does not provide recommendations to buy or sell securities. Terms · Privacy